<DOC>
	<DOCNO>NCT01349595</DOCNO>
	<brief_summary>The purpose study see treat patient high level donor specific alloantibody post-transplant bortezomib might prevent development transplant glomerulopathy preserve allograft function .</brief_summary>
	<brief_title>Impact Proteasome Inhibition Anti-Donor HLA Antibody Production After Kidney Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Female subject either postmenopausal least 1 year screen visit , surgically sterilize , childbearing potential agree practice 2 effective method contraception time sign informed consent form 30 day last dose bortezomib , agree completely abstain heterosexual intercourse . Male subject , even surgically sterilize ( i.e . status postvasectomy ) , must agree 1 following : practice effective barrier contraception entire study treatment period minimum 30 day last dose study drug completely abstain heterosexual intercourse . Kidney transplant recipient ( live decease donor ) receive transplant last 3 year high Donor Specific Antibody ( DSA ) level ( define Mean Fluorescent Intensity level &gt; 2000 solid phase single antigen bead LABscreen assay ) . Patients recipient ABO ( blood type ) incompatible kidney transplant . Patient Glomerular Filtration Rate ( eGFR ) ≤30 m/min time study entry . Patient biopsy proven transplant glomerulopathy ( Banff 2007 cg score ≥2 ) within 2 month prior randomization . Patients biopsyproven acute rejection time randomization define Acute Cellular Rejection Patients document biopsy proven recurrence disease de novo glomerular disease posttransplant prior enrollment . Patient platelet count &lt; 30 x 10 ( 9 ) /L within 14 day enrollment . Patient absolute neutrophil count &lt; 1.0 x 10 ( 9 ) /L within 14 day enrollment . Patient history posttransplant neutropenia mycophenolate base immunosuppressive therapy . Evidence severe liver disease abnormal liver profile ( aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] &gt; 3 time upper limit normal [ ULN ] ) screening . Patient &gt; 1.5 x ULN Total Bilirubin . Patient history myocardial infarction past 3 year prior enrollment New York Heart Association ( NYHA ) Class II IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen must document investigator medically relevant . Patient hypersensitivity bortezomib , boron , mannitol . Female subject pregnant lactating . Serious medical psychiatric illness likely interfere participation clinical study . Cytomegalovirus ( CMV ) seronegative recipient receive transplant CMVseropositive donor . ( CMV recipient CMV donor kidney acceptable ) Epstein Barr Virus ( EBV ) seronegative recipient . History CMV + EBV + viremia since transplantation . History SPELL OUT HCV positivity ( PCR ) . History Posttransplant lymphoproliferative disease . History polyoma virus nephropathy BK virus viremia ( peripheral blood viral load 5000 5,000,000 copies/mL ) . Patients HIVpositive HBsAgpositive . Recipients kidney donor test positive HIV , HBsAg antiHCV . Patients current recent severe systemic ( pathogen detect blood Cerebrospinal fluid ) infection within 4 week prior randomization . Diagnosed treat another malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy . Patient currently receive everolimus , sirolimus , azathioprine one immunosuppressive agent intend remain regimen . Participation clinical trial investigational agent include trial , within 14 day start trial throughout duration trial . Inability perform followup undergo protocol biopsy . Active diabetic neuropathy time treatment initiation . Patient ≥Grade 2 peripheral neuropathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>